Jumi Han
CGBio Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jumi Han as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:02 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06715345 · Efficacy and Safety of Novosis Putty for Degenerative Lumbar DiseaseCGBio Inc. · completed · Degenerative Lumbar Diseases · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:02 UTC. The ranking covers the 200 most relevant of 906 PubMed records, and a shared surname and initials can bring in a namesake. All 906 on PubMed
- 5,442 citationsRCR 181.6
- 1,284 citationsRCR 71.4
- Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.N Engl J Med · 2021970 citationsRCR 57.5
- Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.N Engl J Med · 2018824 citationsRCR 27.7
- Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.J Allergy Clin Immunol · 2020601 citationsRCR 40.1
- Valganciclovir for symptomatic congenital cytomegalovirus disease.N Engl J Med · 2015592 citationsRCR 25.3
- Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.J Thorac Oncol · 2021359 citationsRCR 18.4
- 318 citationsRCR 18.7
- Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.J Allergy Clin Immunol · 2022283 citationsRCR 28.2
- Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.J Thorac Oncol · 2021282 citationsRCR 13.6